Cytochrome P450 enzymes: central players in cardiovascular health and disease.

R. Elbekai,A. El-Kadi

DOI: https://doi.org/10.1016/J.PHARMTHERA.2005.05.011

2006-11-01

Abstract:

What problem does this paper attempt to address?

Clinical management of patients with drug-induced liver injury (DILI)

Einar S Björnsson

DOI: https://doi.org/10.1002/ueg2.12113

Abstract:Drug-induced liver injury (DILI) should be considered in all patients with recent elevation of liver tests without obvious etiology and normal hepatobiliary imaging. There is currently no biomarker that is helpful in diagnosis which relies on clinical and laboratory findings. Diagnosis is dependent on temporal relationship with a recently started drug or herbal and dietary supplement and elevated liver tests with exclusion of competing etiologies. The implicated agent should be discontinued and the patient should be observed closely. This is particularly important in patients with jaundice who have approximately 10% risk of liver related mortality and/or need for liver transplantation. There is no specific therapy for DILI which is only symptomatic such as for itching. Patients with jaundice and coagulopathy usually require hospitalization.
Idiosyncratic drug-induced liver injury: an overview

S Hyder Hussaini,Elizabeth A Farrington

DOI: https://doi.org/10.1517/14740338.6.6.673

Abstract:Drug-induced liver injury (DILI) encompasses a spectrum of clinical disease ranging from mild biochemical abnormalities to acute liver failure. The majority of adverse liver reactions are idiosyncratic, occurring in most instances 5-90 days after the causative medication was last taken. The diagnosis of DILI is clinical, based on history, probability of the suspect medication as a cause of liver injury and exclusion of other hepatic disease. DILI can be hepatocellular (predominant rise in alanine transaminase), cholestatic (predominant rise in alkaline phosphatase) or mixed liver injury. An elevated bilirubin level more than twice the upper limit of normal in patients with hepatocellular liver injury implies severe DILI, with a mortality of approximately 10% and with an incidence rate of 0.7-1.3 per 100,000. Although acute liver failure is rare, 13-17% of all acute liver failure cases are attributed to idiosyncratic drug reactions. Response to drug withdrawal may be delayed up to 1 year with cholestatic liver injury with occasional subsequent progressive cholestasis known as the vanishing bile duct syndrome. Overall, chronic disease may occur in up to 6% even if the offending drug is withdrawn. Antibiotics and NSAIDs are the most common cause of DILI. Statins rarely cause significant liver injury whereas antiretroviral therapy is associated with hepatotoxicity in 10% of treated patients. Multiple mechanisms of DILI have been implicated, including TNF-alpha-activated apoptosis, inhibition of mitochondrial function and neoantigen formation. Risk factors for DILI include age, sex and genetic polymorphisms of drug-metabolising enzymes such as cytochrome P450. In patients with human immunodeficiency virus, the presence of chronic viral hepatitis increases the risk of antiretroviral therapy hepatotoxicity. Over the next decade, the combination of accurate case ascertainment of DILI via clinical networks and the application of genomics and proteomics will hopefully lead to accurate prediction of risk of DILI, so that pharmacotherapy can be optimised with avoidance of adverse hepatic events.
An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

Yao Lvfeng,Zhang Jianzhong,Jin Jie,Li Hongbin,Li Lei,Han Xian,Raza Hafiz Khuram,Li Xiaoyun,Mao Yimin

DOI: https://doi.org/10.1007/s11096-022-01402-x

IF: 2.305

2022-01-01

International Journal of Clinical Pharmacy

Abstract:Background Drug-induced liver injury (DILI) refers to liver damage caused by drugs. DILI poses a significant challenge in the development of new drugs. The management of DILI mainly involves the withdrawal of the offending drug, and there is a lack of specific therapy. This study sought to evaluate the efficacy and safety of compound glycyrrhizin (CG) injections in DILI patients. Aim To evaluate the efficacy and safety of compound glycyrrhizin injections in DILI treatment. Methods The clinical data of DILI patients were collected from a nationwide DILI database. Patients were divided into two groups: the compound glycyrrhizin (CG) group who received CG injections, and the control group who received no treatment. The propensity score matching (PSM) method was applied to obtain an even distribution of characteristics between the two groups. The efficacy of the CG injections was assessed by the analysis of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels between the two groups. Results There were 152 patients in the compound glycyrrhizin group and 512 patients in the control group. The PSM method was used to acquire 152 matched pairs. The compound glycyrrhizin group had a significantly higher overall ALT and AST normalization rate than the control group (43.42% vs. 24.34%, p = 0.0004 and 63.82% vs. 38.82%, p ≤ .0001). There was no difference in the levels of renal and serum biochemical parameters between the two groups. Conclusions CG injections are effective in reducing ALT and AST levels in DILI patients, and their safety is comparable to the control group.
CSH guidelines for the diagnosis and treatment of drug-induced liver injury

Yue-cheng Yu,Yi-min Mao,Cheng-wei Chen,Jin-jun Chen,Jun Chen,Wen-ming Cong,Yang Ding,Zhong-ping Duan,Qing-chun Fu,Xiao-yan Guo,Peng Hu,Xi-qi Hu,Ji-dong Jia,Rong-tao Lai,Dong-liang Li,Ying-xia Liu,Lun-gen Lu,Shi-wu Ma,Xiong Ma,Yue-min Nan,Hong Ren,Tao Shen,Hao Wang,Ji-yao Wang,Tai-ling Wang,Xiao-jin Wang,Lai Wei,Qing Xie,Wen Xie,Chang-qing Yang,Dong-liang Yang,Yan-yan Yu,Min-de Zeng,Li Zhang,Xin-yan Zhao,Hui Zhuang,,,

DOI: https://doi.org/10.1007/s12072-017-9793-2

IF: 9.029

2017-04-12

Hepatology International

Abstract:Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.

gastroenterology & hepatology
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

Yimin Mao,Shiwu Ma,Chenghai Liu,Xiaoyan Liu,Minghua Su,Dongliang Li,Yiling Li,Gongying Chen,Jun Chen,Jinjun Chen,Jingmin Zhao,Xiaoyan Guo,Jieting Tang,Yuzheng Zhuge,Qing Xie,Wen Xie,Rongtao Lai,Dachuan Cai,Qingxian Cai,Yang Zhi,Xiaoyun Li,the Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association

DOI: https://doi.org/10.1007/s12072-023-10633-7

IF: 9.029

2024-02-26

Hepatology International

Abstract:Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.

gastroenterology & hepatology
Idiosyncratic drug-induced liver injury: an update on the 2007 overview

S Hyder Hussaini,Elizabeth Anne Farrington

DOI: https://doi.org/10.1517/14740338.2013.828032

Abstract:Introduction: Idiosyncratic drug induced liver injury (DILI) is rare, with an incidence of approximately 19 per 100,000 treated individuals. Areas covered: An update on the epidemiology, pathogenic mechanisms, diagnosis, outcome, risk factors for idiosyncratic drug-induced hepatotoxicity, specific classes of drug hepatotoxicity and biomarkers to predict DILI are covered. Cumulative drug exposure and HLA phenotypes play an important role in the pathogenesis of DILI. Patients who present with suspected DILI and jaundice should have biliary obstruction and acute viral hepatitis, including hepatitis E excluded. Immune-mediated DILI will respond to steroid therapy. Patients with an elevated bilirubin and a hepatocellular pattern of liver function tests have severe liver injury with a mortality of greater than 10% and a risk of acute liver failure. Women have an increased risk of hepatocellular DILI. Antibiotics, anticonvulsants, and antidepressant therapy remain the commonest causes of DILI in the Western Hemisphere. Statin therapy rarely causes severe liver injury. Expert opinion: The establishment of prospective registries for DILI has provided valuable data on the pathogenesis and outcome of DILI. Drug-specific computerised causality assessment tools should improve the diagnosis of DILI. The clinical utility of genetic polymorphisms associated with drug-specific DILI is limited.
Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

Humberto C Gonzalez,Syed-Mohammed Jafri,Stuart C Gordon

DOI: https://doi.org/10.1016/j.cld.2016.08.012

Abstract:Drug-induced liver injury (DILI) can be predictable or idiosyncratic and has an estimated incidence of approximately 20 cases per 100,000 persons per year. DILI is a common cause of acute liver failure in the United States. No accurate tests for diagnosing DILI exist, and its diagnosis is based on exclusion of other conditions. Managing DILI includes discontinuing the suspected causative agent and in selected cases administering an antidote. Liver support systems are used for long-term support or as a bridge to transplantation and are effective for improving encephalopathy, hyperbilirubinemia, and other liver-related conditions, but whether they improve survival remains uncertain.
Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury

Raj Vuppalanchi,Marwan Ghabril

DOI: https://doi.org/10.1007/s11901-018-0417-7

2018-07-17

Current Hepatology Reports

Abstract:Purpose of ReviewIdiosyncratic drug-induced liver injury (DILI) typically presents acutely with liver test abnormalities, sometimes with associated symptoms of abdominal pain, nausea, vomiting, jaundice, fevers, and rash. Histologic abnormalities in such cases of DILI typically range from lobular or portal hepatitis to hepatocyte necrosis. However, sometimes the drug-related liver injuries present with clinical and/or histological features atypical of garden variety DILI and they may be related to uncommon mechanisms of injury, histologic features, or clinical presentation.Recent FindingsMultiple agents or classes of agents can result in uncommon forms of liver injury that are phenotypically unique and differ from commonly recognized acute DILI. These include unusual presentations of drugs commonly associated with typical acute DILI, such as drug-induced autoimmune hepatitis. Atypical DILI also includes histologically atypical manifestations of DILI, such as nodular regenerative hyperplasia, sinusoidal obstruction syndrome, granulomatous hepatitis, and steatosis/steatohepatitis.SummaryAtypical DILI encompasses recognized patterns of injury associated with specific agents or drug classes. These can manifest by atypical biochemical, clinical, and histopathological signatures. An understanding of these types of liver injury is important for the timely recognition of such atypical DILI.
[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Xiao-Li Wang,Zhao-Hui Yu,Shao-Hua Chen,You-Ming Li

DOI: https://doi.org/10.3321/j.issn:0578-1426.2008.05.011

2008-01-01

Abstract:OBJECTIVE:To analyse the etiology, clinical features and prognosis of drug-induced liver disease (DILD), in order to draw more attention to this problem.METHODS:332 cases of DILD admitted to the First Affiliated Hospital of Zhejiang University from 2000-2006 were retrospectively analysed.RESULTS:A variety of drugs, including herbal medicines (27.1% of our total cases), anti-tuberculosis drugs (13.3%) and immunosuppressive drugs (10.8%) caused drug-induced liver damage. The hepatocellular type (43.1%) was the most common type seen clinically and the mixed type (32.5%) and cholestatic type (24.4%) were somewhat less.CONCLUSIONS:A variety of medicines may cause DILD; herbal medicines, anti-tuberculosis drugs and immunosuppressive drugs were frequently found to be responsible, the hepatocellular type was the most common, while the mixed type and cholestatic type were somewhat less. Serum albumin, total bile acids, direct bilirubin and blood prothrombin time are important predictors of the prognosis of DILD.
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

William R. Treem,Melissa Palmer,Isabelle Lonjon-Domanec,Daniel Seekins,Lara Dimick-Santos,Mark I. Avigan,John F. Marcinak,Ajit Dash,Arie Regev,Eric Maller,Meenal Patwardhan,James H. Lewis,Don C. Rockey,Adrian M. Di Bisceglie,James W. Freston,Raul J. Andrade,Naga Chalasani

DOI: https://doi.org/10.1007/s40264-020-01014-2

2020-11-03

Drug Safety

Abstract:With the widespread development of new drugs to treat chronic liver diseases (CLDs), including viral hepatitis and nonalcoholic steatohepatitis (NASH), more patients are entering trials with abnormal baseline liver tests and with advanced liver injury, including cirrhosis. The current regulatory guidelines addressing the monitoring, diagnosis, and management of suspected drug-induced liver injury (DILI) during clinical trials primarily address individuals entering with normal baseline liver tests. Using the same laboratory criteria cited as signals of potential DILI in studies involving patients with no underlying liver disease and normal baseline liver tests may result in premature and unnecessary cessation of a study drug in a clinical trial population whose abnormal and fluctuating liver tests are actually due to their underlying CLD. This position paper focuses on defining best practices for the detection, monitoring, diagnosis, and management of suspected acute DILI during clinical trials in patients with CLD, including hepatitis C virus (HCV) and hepatitis B virus (HBV), both with and without cirrhosis and NASH with cirrhosis. This is one of several position papers developed by the IQ DILI Initiative, comprising members from 16 pharmaceutical companies in collaboration with DILI experts from academia and regulatory agencies. It is based on an extensive literature review and discussions between industry members and experts from outside industry to achieve consensus regarding the recommendations. Key conclusions and recommendations include (1) the importance of establishing laboratory criteria that signal potential DILI events and that fit the disease indication being studied in the clinical trial based on knowledge of the natural history of test fluctuations in that disease; (2) establishing a pretreatment value that is based on more than one screening determination, and revising that baseline during the trial if a new nadir is achieved during treatment; (3) basing rules for increased monitoring and for stopping drug for potential DILI on multiples of baseline liver test values and/or a threshold value rather than multiples of the upper limit of normal (ULN) for that test; (4) making use of more sensitive tests of liver function, including direct bilirubin (DB) or combined parameters such as aspartate transaminase:alanine transaminase (AST:ALT) ratio or model for end-stage liver disease (MELD) to signal potential DILI, especially in studies of patients with cirrhosis; and (5) being aware of potential confounders related to complications of the disease being studied that may masquerade as DILI events.

pharmacology & pharmacy,public, environmental & occupational health,toxicology
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

Harshad Devarbhavi,Guruprasad Aithal,Sombat Treeprasertsuk,Hajime Takikawa,Yimin Mao,Saggere M. Shasthry,Saeed Hamid,Soek Siam Tan,Cyriac Abby Philips,Jacob George,Wasim Jafri,Shiv K. Sarin,

DOI: https://doi.org/10.1007/s12072-021-10144-3

IF: 9.029

2021-02-27

Hepatology International

Abstract:Idiosyncratic drug-induced liver injury mimics acute and chronic liver disease. It is under recognized and underrecognised because of the lack of pathognomonic diagnostic serological markers. Its consequences may vary from being asymptomatic to self-limiting illness to severe liver injury leading to acute liver failure. Its incidence is likely to be more common in Asia than other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complimentary medicines in Asian countries. This APASL consensus guidelines on DILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.

gastroenterology & hepatology
Drug-induced liver injury: a comprehensive review

Tom Hosack,Djamil Damry,Sujata Biswas

DOI: https://doi.org/10.1177/17562848231163410

2023-01-01

Therapeutic Advances in Gastroenterology

Abstract:Drug-induced liver injury (DILI) remains a challenge in clinical practice and is still a diagnosis of exclusion. Although it has a low incidence amongst the general population, DILI accounts for most cases of acute liver failure with a fatality rate of up to 50%. While multiple mechanisms of DILI have been postulated, there is no clear causal relationship between drugs, risk factors and mechanisms of DILI. Current best practice relies on a combination of high clinical suspicion, thorough clinical history of risk factors and timeline, and extensive hepatological investigations as supported by the international Roussel Uclaf Causality Assessment Method criteria, the latter considered a key diagnostic algorithm for DILI. This review focuses on DILI classification, risk factors, clinical evaluation, future biomarkers and management, with the aim of facilitating physicians to correctly identify DILI early in presentation.

gastroenterology & hepatology
Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase

Hui-Min Xu,Yan Chen,Jie Xu,Quan Zhou

DOI: https://doi.org/10.3748/wjg.v18.i41.5972

IF: 5.374

2012-01-01

World Journal of Gastroenterology

Abstract:AIM: To identify the proportion, causes and the nature of drug-induced liver injury (DILI) in patients with notably elevated alanine aminotransferase (ALT).METHODS: All the inpatients with ALT levels above 10 times upper limit of normal range (ULN) were retrospectively identified from a computerized clinical laboratory database at our hospital covering a 12-mo period. Relevant clinical information was obtained from medical records. Alternative causes of ALT elevations were examined for each patient, including biliary abnormality, viral hepatitis, hemodynamic injury, malignancy, DILI or undetermined and other causes. All suspected DILI cases were causality assessed using the Council for International Organizations of Medical Sciences scale, and only the cases classified as highly probable, probable, or possible were diagnosed as DILI. Comments related to the diagnosis of DILI in the medical record and in the discharge letter for each case were also examined to evaluate DILI detection by the treating doctors.RESULTS: A total of 129 cases with ALT > 10 ULN were identified. Hemodynamic injury (n = 46, 35.7%), DILI (n = 25, 19.4%) and malignancy (n = 21, 16.3%) were the top three causes of liver injury. Peak ALT values were lower in DILI patients than in patients with hemodynamic injury (14.5 ± 5.6 ULN vs 32.5 ± 30.7 ULN, P = 0.001). Among DILI patients, one (4%) case was classified as definite, 19 (76%) cases were classified as probable and 5 (20%) as possible according to the CIOMS scale. A hepatocellular pattern was observed in 23 (92%) cases and mixed in 2 (8%). The extent of severity of liver injury was mild in 21 (84%) patients and moderate in 4 (16%). Before discharge, 10 (40%) patients were recovered and the other 15 (60%) were improved. The improved patients tended to have a higher peak ALT (808 ± 348 U/L vs 623 ± 118 U/L, P = 0.016) and shorter treatment duration before discharge (8 ± 6 d vs 28 ± 12 d, P = 0.008) compared with the recovered patients. Twenty-two drugs and 6 herbs were found associated with DILI. Antibacterials were the most common agents causing DILI in 8 (32%) cases, followed by glucocorticoids in 6 (24%) cases. Twenty-four (96%) cases received treatment of DILI with at least one adjunctive drug. Agents for treatment of DILI included anti-inflammatory drugs (e.g., glycyrrhizinate), antioxidants (e.g., glutathione, ademetionine 1,4-butanedisulfonate and tiopronin), polyene phosphatidyl choline and herbal extracts (e.g., protoporphyrin disodium and silymarin). Diagnosis of DILI was not mentioned in the discharge letter in 60% of the cases. Relative to prevalent cases and cases from wards of internal medicine, incident cases and cases from surgical wards had a higher risk of missed diagnosis in discharge letter [odds ratio (OR) 32.7, 95%CI (2.8-374.1), and OR 58.5, 95%CI (4.6-746.6), respectively].CONCLUSION: DILI is mostly caused by use of antibacterials and glucocorticoids, and constitutes about one fifth of hospitalized patients with ALT > 10 ULN. DILI is underdiagnosed frequently.

gastroenterology & hepatology
Effects of sodium dodecylsulphate, dye concentration and paraprotein on coomassie blue dye-binding assays for protein in urine.

C. W. Lim,W. Chisnall,Y. Stokes,R. Pratt,M. Crooke

DOI: https://doi.org/10.1016/S0009-9120(88)80081-X

IF: 3.625

1988-10-01

Clinical Biochemistry

Abstract:
Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Kasumi Satoh,Manabu Okuyama,Nobuhisa Hirasawa,Hajime Nakae

DOI: https://doi.org/10.7759/cureus.33558

2023-01-09

Cureus

Abstract:Drug-induced liver injury (DILI) is difficult to diagnose as it presents with a wide variety of clinical manifestations and there is no established specific biomarker. However, clinicians require expertise in diagnosing DILI as it can lead to critical illness, is relatively common, and can be caused by a variety of drugs, herbal medicines, and supplements. A 67-year-old male was admitted to the hospital with a fever, jaundice, and fatigue. Abdominal ultrasonography, computed tomography, and magnetic resonance cholangiopancreatography revealed no morphological abnormalities in the hepatobiliary system. On the third day of hospitalization, the liver damage and acute kidney injury progressed, and the patient was transferred to our intensive care unit. To further investigate the cause of multiple organ damage, the patient underwent repeated history taking and additional laboratory testing. In addition to the common causes of hepatic and renal damage, we also tested for rickettsiosis and leptospirosis, as the patient reported partaking regularly in outdoor leisure activities. On day seven of hospitalization, the patient recalled taking over-the-counter herbal flu medications approximately five days prior to admission; therefore, we suspected DILI and performed a drug-induced lymphocyte stimulation test (DLST). The DLST was positive for one drug. As other causes had been ruled out, the patient was diagnosed with severe DILI. The clinical course of the patient was observed with the patient's laboratory data and fever improving spontaneously. This case taught us several important lessons for the investigation of liver injury. Firstly, even with over-the-counter drugs, liver injury can be severe. Secondly, while the DLST is available for investigating DILI, false positives, especially for medicinal herbs, should be noted, and it is necessary to adequately rule out other diseases. Finally, when the cause of liver injury is unclear, patient history taking should be repeated carefully.
Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Meng Li,Qiong Luo,Yanyan Tao,Xin Sun,Chenghai Liu

DOI: https://doi.org/10.3389/fphar.2021.806249

IF: 5.6

2022-01-05

Frontiers in Pharmacology

Abstract:Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed.

pharmacology & pharmacy
An analysis on the clinical features and risk factors associated with the prognosis of patients with drug-induced liver injury

Qian Wei,Lei Li,Xiaoqing Zeng,Jie Yin,Jinsheng Guo

DOI: https://doi.org/10.37349/edd.2023.00021

2023-01-01

Exploration of Digestive Diseases

Abstract:Aim: This is a Chinese population-based study aimed to determine the causes and clinical features of drug-induced liver injury (DILI) from traditional Chinese medicines (TCMs) and current Western medicines (WMs) and identify the risk factors of drug-induced liver failure (DILF) and chronic DILI for early recognition and better management. Methods: The medical records of patients who were diagnosed with DILI for at least six-month follow-up between January 2018 to December 2020 were reviewed and investigated. The risk factors of DILF and chronic DILI were identified by univariate and multivariate logistic regression analysis. Results: TCMs (47.5%) including herbal medicine (83.0% in TCM-induced DILI) and some Chinese patent drugs were the leading cause of DILI in the present study. Cholestatic type was more associated with severe and chronic DILI. Pre-existing gallbladder disease, initial total bilirubin (TBIL), initial prothrombin time (PT), initial antinuclear antibodies (ANA), and clinical classification are independent risk factors for DILF. Prolonged T0.5AST and T0.5GGT were independent risk factors for chronic DILI [area under the curve (AUC) = 0.812, 95% confidence interval (CI): 0.748–0.876, P < 0.001] with cut-off values of 8.5 days and 29.5 days, respectively. Conclusions: TCMs especially herbal medicine were the leading causes of DILI, and the risk of developing severe DILI was associated with pre-existing gallbladder disease, clinical classification, initial TBIL, PT, and ANA. T0.5AST and T0.5GGT might serve as indicators for chronicity.
Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Ashwin Rao,Jody A Rule,Bilal Hameed,Daniel Ganger,Robert J Fontana,William M Lee

DOI: https://doi.org/10.14309/ajg.0000000000001655

2022-04-01

Abstract:Introduction: Idiosyncratic drug-induced liver injury (DILI) is the second leading cause of acute liver failure (ALF) in the United States. Our study aims were to characterize secular trends in the implicated agents, clinical features, and outcomes of adults with DILI ALF over a 20-year period. Methods: Among 2,332 patients with ALF enrolled in the ALF Study Group registry, 277 (11.9%) were adjudicated as idiosyncratic DILI ALF (INR ≥ 1.5 and hepatic encephalopathy) through expert opinion. The 155 cases in era 1 (January 20, 1998-January 20, 2008) were compared with the 122 cases in era 2 (January 21, 2008-January 20, 2018). Results: Among 277 cases of DILI ALF, 97 different agents, alone or in combination, were implicated: antimicrobials, n = 118 (43%); herbal/dietary supplements (HDS), n = 42 (15%); central nervous system agents/illicit substances, n = 37 (13%); oncologic/biologic agents, n = 29 (10%); and other, n = 51 (18%). Significant trends over time included (i) an increase in HDS DILI ALF (9.7% vs 22%, P < 0.01) and decrease in antimicrobial-induced DILI ALF (45.8% vs. 38.5%, P = 0.03) and (ii) improved overall transplant-free survival (23.5%-38.7%, P < 0.01) while the number of patients transplanted declined (46.4% vs 33.6%, P < 0.03). Discussion: DILI ALF in North America is evolving, with HDS cases rising and other categories of suspect drugs declining. The reasons for a significant increase in transplant-free survival and reduced need for liver transplantation over time remain unclear but may be due to improvements in critical care, increased NAC utilization, and improved patient prognostication.
Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review

Hao Niu,Edmond Atallah,Ismael Alvarez-Alvarez,Inmaculada Medina-Caliz,Guruprasad P. Aithal,Cigdem Arikan,Raul J. Andrade,M. Isabel Lucena

DOI: https://doi.org/10.1007/s40264-022-01224-w

2022-08-26

Drug Safety

Abstract:Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF). The evidence for treatment of DILI in children is scarce.

pharmacology & pharmacy,public, environmental & occupational health,toxicology
[An analysis on clinical characteristics and prognosis-related risk factors in patients with drug-induced liver injury].

Q Wei,L Li,X Q Zeng,Bai He Ti Ya Er Abidan,J Yin,H Gao,J S Guo

DOI: https://doi.org/10.3760/cma.j.cn501113-20240201-00072

2024-01-01

Abstract:Objective: To explore the drugs and clinical characteristics causing drug-induced liver injury (DILI) in recent years, as well as identify drug-induced liver failure, and chronic DILI risk factors, in order to better manage them timely. Methods: A retrospective investigation and analysis was conducted on 224 cases diagnosed with DILI and followed up for at least six months between January 2018 and December 2020. Univariate and multivariate logistic regression analyses were used to identify risk factors for drug-induced liver failure and chronic DILI. Results: Traditional Chinese medicine (accounting for 62.5%), herbal medicine (accounting for 84.3% of traditional Chinese medicine), and some Chinese patent medicines were the main causes of DILI found in this study. Severe and chronic DILI was associated with cholestatic type. Preexisting gallbladder disease, initial total bilirubin, initial prothrombin time, and initial antinuclear antibody titer were independent risk factors for DILI. Prolonged time interval between alkaline phosphatase (ALP) and alanine aminotransferase (ALT) falling from the peak to half of the peak (T(0.5ALP) and T(0.5ALT)) was an independent risk factor for chronic DILI [area under the receiver operating characteristic curve (AUC) = 0.787, 95%CI: 0.697~0.878, P < 0.001], with cutoff values of 12.5d and 9.5d, respectively. Conclusion: Traditional Chinese medicine is the main contributing cause of DILI. The occurrence risk of severe DILI is related to preexisting gallbladder disease, initial total bilirubin, prothrombin time, and antinuclear antibodies. T(0.5ALP) and T(0.5ALT) can be used as indicators to predict chronic DILI.

Cytochrome P450 enzymes: central players in cardiovascular health and disease.

Clinical management of patients with drug-induced liver injury (DILI)

Idiosyncratic drug-induced liver injury: an overview

An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

CSH guidelines for the diagnosis and treatment of drug-induced liver injury

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

Idiosyncratic drug-induced liver injury: an update on the 2007 overview

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

Drug-induced liver injury: a comprehensive review

Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase

Effects of sodium dodecylsulphate, dye concentration and paraprotein on coomassie blue dye-binding assays for protein in urine.

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

An analysis on the clinical features and risk factors associated with the prognosis of patients with drug-induced liver injury

Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review

[An analysis on clinical characteristics and prognosis-related risk factors in patients with drug-induced liver injury].